Core Insights - The company aims to enhance its market competitiveness in the food, nutrition, and beauty sectors by investing in Peisheng Biotechnology to promote the application of new raw materials in consumer products [1][2] - The establishment of Beijing Kaiyuan Juliy aims to leverage the capital and talent resources in the capital city to improve the company's professional capabilities in business expansion and capital operations, driving a dual strategy of "industry + capital" [1] Product Pricing and Market Strategy - The sales prices of products such as erythritol, blended sugars, and allulose will fluctuate based on specifications, business conditions, and market competition, with a dynamic adjustment throughout the year [1] - The company has a competitive edge in production technology and cost control for tagatose, which is currently in an active promotion phase, with market pricing being continuously optimized based on market feedback [1] New Product Development - The company is committed to innovation-driven growth, focusing on synthetic biology and advancing new product research and industrialization [2] - A new 10,000-ton production line for allulose is under rapid construction, aiming to secure a first-mover advantage in the fast-growing market once approved for domestic use [2] - The existing 85,000-ton erythritol production line is undergoing upgrades to enable flexible manufacturing capabilities across multiple products, significantly reducing new product line construction costs and enhancing market responsiveness [2] - The company is optimizing production processes for high-activity biological raw materials like glycerol glycosides and sweet tea glycosides, with plans for small-scale production based on technology maturity and market demand [2]

Group 1: Company Strategy and Investments - The core purpose of investing in Peisheng Biotechnology is to promote the application of new raw materials in C-end products, enhancing market competitiveness in food, nutrition, and beauty sectors [4] - The establishment of Beijing Kaiyuan Juliy aims to leverage talent and resources in the capital to enhance business expansion and capital operation professionalism [4] Group 2: Production Capacity and Flexibility - The 85,000-ton project is an upgrade of the existing erythritol production line, enabling flexible manufacturing of multiple products based on market demand [4] - The 80,000-ton project focuses on upstream integration, producing liquid glucose from corn, ensuring stable raw material supply for various products [4] Group 3: Employee Stability - The number of employees remains stable, with no layoffs reported, emphasizing talent cultivation and a supportive work environment [4] Group 4: Market Performance and Sales - Erythritol revenue was 515.4 million yuan, with a sales price exceeding 10,000 yuan/ton, leading to a sales volume of less than 50,000 tons due to industry competition and EU anti-dumping measures [7] - Domestic market sales increased by 70.23% year-on-year, with the number of domestic distributors rising by 117, reflecting the growing demand for reduced sugar products [9] Group 5: Regulatory Challenges - The EU imposed a 156.7% anti-dumping duty on the company's products, effective for five years, prompting adjustments in production processes to comply with cost assessment rules [10] - The company is actively responding to the US "double anti" investigation, which has impacted sales in the US market, and is developing contingency plans [14] Group 6: Product Development and Innovation - The second 10,000-ton production line for allulose is under rapid construction, aiming to capture market share once approved for domestic use [13] - The company is enhancing production processes for high-activity biological raw materials, expanding its product range beyond erythritol [13] Group 7: Future Outlook and Shareholder Returns - The company has a three-year shareholder return plan (2024-2026) focusing on stable profit distribution while considering profitability and cash flow [7] - The company aims to diversify its market strategy, reducing reliance on single markets and enhancing resilience against policy risks [15]

Core Insights - Shandong Sanyuan Biotechnology Co., Ltd. reported a revenue of 712.90 million yuan for 2024, representing a year-on-year growth of 42.72% [1][2] - The net profit attributable to shareholders reached 104.95 million yuan, an increase of 87.47% compared to the previous year [1][2] - The company's net profit after deducting non-recurring gains and losses was 102.48 million yuan, also reflecting an 87.04% year-on-year growth [1][2] Financial Performance - In Q4 2024, the company achieved a revenue of 198 million yuan, which is a 33.49% increase year-on-year [2] - The net profit for Q4 2024 was 23.94 million yuan, up 67.34% from the same quarter last year [2] - The net profit after deducting non-recurring gains and losses for Q4 2024 was 23.01 million yuan, showing a 64.73% increase year-on-year [2] Profitability Metrics - The gross margin for 2024 was reported at 11.11%, an increase of 8.06 percentage points compared to the previous year [3] - The net profit margin for 2024 was 14.72%, which is an increase of 3.51 percentage points year-on-year [3] Expense Analysis - Sales expenses increased by 24.81% year-on-year, while management expenses rose by 27.16% [3] - Research and development expenses decreased by 18.61% compared to the previous year [3] Cash Flow Overview - The net cash flow from operating activities decreased by 123.82% year-on-year, primarily due to a change in payment methods and the need to repay previously issued bank acceptance bills [3] - The net cash flow from investing activities increased by 159.15% year-on-year, mainly due to the redemption of certain large bank deposits [3] - The net cash flow from financing activities grew by 31.19% year-on-year, attributed to higher dividend distributions in 2023 [3] Company Background - Sanyuan Biotechnology was established on March 4, 2022, and was listed on February 10, 2022 [3] - The company's main business includes the research, production, and sales of food additives, specifically erythritol and its compound products [3]

证券代码：301206 证券简称：三元生物 公告编号：2025-047 山东三元生物科技股份有限公司 1 / 2 截至 2025 年 4 月 30 日，公司通过股票回购专用账户以集中竞价交易方式累 计回购公司股份 1,875,700 股，占公司总股本的 0.93%，最高成交价为 27.85 元/ 股，最低成交价为 23.51 元/股，累计成交总金额为 47,496,804.91 元（不含交易 费用）。本次回购进展符合公司回购股份方案及相关法律法规的要求。 二、其他说明 公司回购股份时间、回购股份数量、回购股份价格及集中竞价交易的委托时 段等均符合《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》第十 七条、十八条及公司回购股份方案的相关规定，具体如下： 1、公司未在下列期间内回购公司股份： 关于回购公司股份的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"） 于 2024 年 7 月 8 日 召开了第四届董事会第二十三次会议，会议审议通过了《关于回购公司股份方案 的议案》，同意公司使用自有资金以集 ...

保龄宝2024年实现总营业收入24亿元，同比减少4.8%；实现归母净利润1.1亿元，同比增长106%，业绩 跌幅也较上年同期好转。 记者注意到，代糖股的业绩回升，主要与2024年赤藓糖醇整体市场改善有关。2024年三元生物赤藓糖醇 业务收入5.2亿元，同比增长26.4%，毛利率从2023年的1.1%上升至2024年的8.3%，带动了整体利润水平 的提升。保龄宝的情况也类似，2024年赤藓糖醇销售收入同比增长52.6%，减糖甜味剂业务毛利率也提 升了7.8个百分点。 在2021年前后，受市场需求激增和利润水平良好的影响，赤藓糖醇迎来一轮扩产潮，到2023年5月，国 内赤藓糖醇产能已达到38万吨/年，远超全球市场的实际需求，过剩也带来了激烈的价格战。赤藓糖醇 的价格从4万元/吨跌至9500元/吨。2024年，随着过剩产能逐步出清和行业整合，赤藓糖醇价格回升， 带动了代糖股的业绩回升。 三元生物称，目前国内赤藓糖醇行业的竞争格局有所缓解，但市场价格尚未显著回升，仍处于相对低位 运行阶段，市场机制将迫使一部分企业关停或转产其他产品，随着产能的逐步出清，赤藓糖醇市场有望 逐步恢复相对稳定的供需格局，产品价格也会趋于合理 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-046 山东三元生物科技股份有限公司 关于使用暂时闲置超募资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2025 年 1 月 24 日 召开了第五届董事会第五次会议和第五届监事会第五次会议，于 2025 年 2 月 10 日召开了 2025 年第二次临时股东大会，上述会议审议通过了《关于使用暂时闲 置超募资金进行现金管理的议案》。同意公司在不影响日常生产经营和保证超募 资金安全使用的前提下，拟使用不超过 190,000 万元人民币暂时闲置超募资金进 行现金管理。使用期限自公司 2025 年第二次临时股东大会会议审议通过之日起 12 个月内有效，在上述投资额度和使用期限内资金可滚动使用。公司授权管理 层在上述额度范围及期限内行使投资决策、签署相关文件等事宜，具体事项由公 司财务部负责组织实施。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于使用暂时闲置超募 ...

Industry Overview - Allulose, or D-Psicose, is a rare sugar found in small amounts in natural foods like raisins and figs, characterized by its white powder form and low caloric content [1][2] - The global allulose market is projected to reach $14.7 million by 2024 and is expected to grow to $43.6 million by 2032, driven by favorable policies and a global trend towards reduced sugar consumption [1][11] Market Dynamics - The allulose market is expanding rapidly in beverage and baking sectors, with China being the largest consumer market, holding approximately 80.45% of the market share, followed by Japan and South Korea [11][14] - The approval of allulose for use in various food products in multiple countries, including the U.S. and Australia, is facilitating its market entry, while the EU is expected to approve it within 2-3 years [11][13] Production and Technology - The primary production method for allulose is biological conversion, utilizing D-Psicose 3-epimerase to convert fructose into allulose, with key players including Jinhe Industrial, Baolingbao, and Sanyuan Bio [9][16] - Recent advancements in enzyme engineering have improved the yield of allulose production to 88.8%, significantly reducing raw material costs [26] Competitive Landscape - Major global players in the allulose market include CJ CheilJedang, Samyang, Tate & Lyle, and Matsutake, which have established production capabilities and technological advantages [18][29] - Domestic companies in China, such as Jinhe Industrial and Baolingbao, are in the process of expanding their production capacities, with potential domestic capacity exceeding 286,100 tons [20][26] Future Trends - The market is expected to experience a surge in industrial applications due to policy support, with the potential for allulose to be widely used in sugar-free beverages and baked goods by 2025 [25] - Health-conscious consumer trends are driving demand for low-calorie sweeteners like allulose, which is anticipated to see significant growth in the functional food sector [28][29]

证券代码：301206 证券简称：三元生物 公告编号：2025-040 山东三元生物科技股份有限公司 关于前期会计差错更正及追溯调整的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、山东三元生物科技股份有限公司（以下简称"公司"）本次对前期会计 差错更正及追溯调整，将影响 2023 年度、2024 年一季度、半年度、三季度相关 财务报告数据及披露信息。 2、公司本次对前期会计差错更正及追溯调整，不会对归属于上市公司股东 的净资产、归属于上市公司股东的净利润造成重大影响，不会导致公司已披露的 相关年度报表出现盈亏性质的改变。 3、本次前期会计差错更正及追溯调整事项给广大投资者造成的不便，公司 深表歉意。今后公司将持续提升治理水平和规范运作水平，努力提高信息披露质 量，切实保障公司及全体股东的利益。 公司于 2025 年 4 月 28 日召开了第五届董事会第六次会议、第五届监事会第 六次会议，会议审议通过了《关于前期会计差错更正及追溯调整的议案》。同意 公司根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》《公 开发行证券的公 ...

证券代码：301206 证券简称：三元生物 公告编号：2025-043 山东三元生物科技股份有限公司 2024 年年度股东大会通知公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）第五届董事会第六次 会议决定于 2025 年 5 月 26 日（星期一）召开公司 2024 年年度股东大会，现将 本次会议有关事项通知如下： 一、召开会议的基本情况 （一）股东大会届次：2024 年年度股东大会 （二）股东大会的召集人：公司董事会。 （三）会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 （四）会议召开的日期、时间： 1、现场会议召开时间：2025 年 5 月 26 日（星期一）15:00 2、网络投票时间：2025 年 5 月 26 日（星期一） （1）通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 26 日 9:15-9:25，9:30-11:30，13:00-15:00。 （2）通过深圳证券交易所互联网系统投票的时间为 2025 ...

第五届监事会第六次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、会议召开和出席情况 山东三元生物科技股份有限公司（以下简称"公司"）第五届监事会第六次 会议于 2025 年 4 月 28 日下午 2:30 在公司会议室以现场方式召开。会议通知于 4 月 17 日以书面、电话方式通知到各位监事，本次会议应到监事 3 人，实到监事 3 人，会议由监事会主席阎光浩主持，会议的召集、召开和表决程序符合《公司 法》和《公司章程》的有关规定，所作决议合法有效。 二、议案审议情况 本次会议以记名投票表决方式表决通过如下议案： 证券代码：301206 证券简称：三元生物 公告编号：2025-042 山东三元生物科技股份有限公司 际经营情况，公司财务部编制了 2024 年度财务决算报告。 经审核，监事会认为：《2024 年度财务决算报告》客观、真实地反映了公司 2024 年度的财务状况和经营成果。 表决结果：3 票同意，0 票反对，0 票弃权； （一）审议通过《2024 年度监事会工作报告》； 公司监事会主席阎光浩先生代表监事会作 2024 年度监事会工作报告 ...